BiotechTube

Inclisiran Sodium for injection + Placebo + Placebos

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Homozygous Familial Hypercholesterolemia

Conditions

Homozygous Familial Hypercholesterolemia

Trial Timeline

Feb 6, 2019 → Sep 9, 2021

NCT ID
NCT03851705

About Inclisiran Sodium for injection + Placebo + Placebos

Inclisiran Sodium for injection + Placebo + Placebos is a phase 3 stage product being developed by Novartis for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03851705. Target conditions include Homozygous Familial Hypercholesterolemia.

What happened to similar drugs?

1 of 16 similar drugs in Homozygous Familial Hypercholesterolemia were approved

Approved (1) Terminated (0) Active (15)
✅evolocumabAmgenApproved
🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
🔄Rosuvastatin 20mgAstraZenecaPhase 3
🔄Inclisiran + PlaceboNovartisPhase 3
🔄InclisiranNovartisPhase 3
🔄Inclisiran + PlaceboNovartisPhase 3
🔄Lumacaftor Plus Ivacaftor Combination + Ivacaftor + PlaceboVertex PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03851705Phase 3Completed

Competing Products

20 competing products in Homozygous Familial Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
40
Rosuvastatin 20mgAstraZenecaPhase 3
40
Inclisiran + PlaceboNovartisPhase 3
40
InclisiranNovartisPhase 3
44
INC280 + BuparlisibNovartisPhase 1/2
24
Inclisiran + PlaceboNovartisPhase 3
47
Evolocumab + PlaceboAmgenPhase 2/3
38
evolocumabAmgenApproved
43
MBX-8025 50 mg (Dose Escalation Period 1) + MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) + MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)Gilead SciencesPhase 2
35
IBI306 + IBI306Innovent BiologicsPhase 2/3
38
BMS-986504 + [14C]-BMS-986504Bristol Myers SquibbPhase 1
36
Lumacaftor Plus Ivacaftor Combination + Ivacaftor + PlaceboVertex PharmaceuticalsPhase 3
40
Placebo + Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
40
Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
40
Alirocumab + PlaceboSanofiPhase 3
40
AK102 + Statins + EzetimibeAkesoPhase 2
35
EvinacumabRegeneron PharmaceuticalsPhase 3
40
evinacumabRegeneron PharmaceuticalsPhase 3
40
REGN1500 250 mg SC/15 mg/kg IV/450 mg SCRegeneron PharmaceuticalsPhase 2
35
EvinacumabRegeneron PharmaceuticalsPre-clinical
26